ClinicalTrials.gg

Program

elunetirom

Its studies are mostly in Bipolar Disorder · Depressive Disorder, Major, led by Autobahn Therapeutics.

Furthest: phase 2, since Sep 30, 20244 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Autobahn Therapeutics42 open or runningphase 2since Sep 30, 2024Aug 19, 2022none ahead

Also a collaborator on its studies: novotech-australia-pty-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2022First study: phase 1 study in MDDFirst studyNCT05528315 · 48 enrolled · Australia
  2. Sep 30, 2024Phase 2 study in Depressive Disorder, MajorNCT06633016 · 230 planned · United States
  3. Feb 18, 2025Phase 2 study in Bipolar DisorderNCT06869187 · 35 enrolled · United States
  4. May 29, 2026Phase 1 study in HealthyNCT07652697 · 18 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07652697Healthy · United States1CompletedFeb 17, 202518
NCT06869187Bipolar Disorder · United States2Active, not recruitingApr 22, 202635
NCT06633016Depressive Disorder, Major · United States2RecruitingJun 2026230
NCT05528315MDD · Australia1CompletedJun 26, 202348

How it is read

Names in the registry

  • “ABX-002”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.